Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Also known as Cand5
bevasiranib · 3 trials · 2 indications
| Arm | Type | Description |
|---|---|---|
| 1 | EXPERIMENTAL | 3.0 mg/eye dose group |
| 2 | EXPERIMENTAL | 1.5 mg/eye dose group |
| 3 | EXPERIMENTAL | 0.2 mg/eye dose group |
| 4 | EXPERIMENTAL | 1.5 mg bevasiranib in the study eye |
| 5 | EXPERIMENTAL | 3.0 mg bevasiranib in the study eye. |
| Name | Type | Description |
|---|---|---|
| bevasiranib | DRUG | - |
Inclusion Criteria: 1. Patients must be male or female age 21 or older. 2. Patient must sign (and be given) a copy of the written informed consent form. 3. Patients must have the diagnosis of diabetes mellitus (type 1 or type 2). Patients with the following will be considered to be sufficient evide...
Top 16 of 17 competitors
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| EyePoint, Inc. | EYPT | 2 | PHASE3 | EYP-1901 |
| 4D Molecular Therapeutics, Inc. | FDMT | 2 | PHASE3 | 4D-150, EYELEA |
| Regeneron Pharmaceuticals, Inc. | REGN | 1 | PHASE3 | Aflibercept |
| Hoffmann-La Roche | RHHBY | 6 | PHASE3 | Ranibizumab, Susvimo, RO7497372, RO7823653, Faricimab |
| Merck & Co., Inc. | MRK | 2 | PHASE3 | MK-8748 |
| AbbVie, Inc. | ABBV | 2 | PHASE2 | Surabgene Lomparvovec |
| Outlook Therapeutics, Inc. | OTLK | 1 | PHASE3 | ONS-5010 |
| Kodiak Sciences, Inc. | KOD | 1 | PHASE3 | Tabirafusp tedromer |
| Alvotech | ALVO | 1 | PHASE3 | AVT29 |
| Kiora Pharmaceuticals, Inc. | KPRX | 1 | PHASE2 | KIO-104 |
| REGENXBIO, Inc. | RGNX | 1 | PHASE2 | RGX-314 |
| BioAge Labs, Inc. | BIOA | 1 | PHASE2 | BGE-102 |
| Ocugen Inc | OCGN | 1 | PHASE1 | OCU200 |
| Surrozen Inc | SRZN | 1 | PHASE1 | SZN-8141 |
| Adverum Biotechnologies, Inc. | ADVM | 1 | - | ADVM-022 |
| Bayer | BAYRY | 1 | - | Aflibercept |
Bevasiranib is an investigational ophthalmology drug studied for diabetic macular edema and macular degeneration, including wet age-related macular degeneration. It was developed by Opko Health Inc. and has been evaluated in Phase 2 clinical trials. It is not described as approved, so it remains an investigational candidate rather than an established therapy.
Bevasiranib targets TLR3 and VEGFA. It is classified as an activator within its target class, and it is a small molecule modality. Targeting VEGFA relates to vascular signaling in the eye, while TLR3 is an immune-related receptor. These targets were the basis for its study in retinal conditions involving abnormal blood vessel activity.
Bevasiranib is developed by Opko Health Inc., which trades under the ticker OPK. The company sponsored the clinical studies of the drug in ophthalmology indications. Opko Health is the developer associated with bevasiranib across its macular degeneration and diabetic macular edema programs.
Bevasiranib is in Phase 2 development. It is an investigational drug and is not described as FDA approved. Its clinical program includes completed Phase 1 and Phase 2 studies, with no active trials currently listed. The completed trials enrolled a total of 135 participants across the studied indications.
Bevasiranib has been studied in completed trials including NCT00722384, an open-label Phase 1 tolerability study of five dose levels in macular degeneration, and NCT00306904, a Phase 2 safety and efficacy study in diabetic macular edema. A third completed Phase 2 trial, NCT00259753, evaluated it in wet age-related macular degeneration.
Yes, bevasiranib is also known as Cand5. The name Cand5 appears in the titles of its clinical trials, including the Phase 2 studies in diabetic macular edema and wet age-related macular degeneration. Readers searching for Cand5 are looking at the same investigational ophthalmology drug developed by Opko Health Inc.